Difference between revisions of "Combining-Valproic acid-Lithium"

From Psychiatrienet
Jump to: navigation, search
 
(2 intermediate revisions by the same user not shown)
Line 3: Line 3:
 
| add = lithium
 
| add = lithium
 
| info =  
 
| info =  
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
+
* Lithium and valproic acid are the most commonly used mood-stabilizing agents.<ref name="freeman">{{Pubmed|9433333|Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21}}</ref>
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
+
* The combination of lithium and valproate appears to be well tolerated and effective in treating bipolar illness.<ref name="freeman"/>
 +
* Addition of lithium to valproic acid is the treatment of choice for acute mania with partial but inadequate response to valproate.<ref name="freeman"/> 
 +
* This combination may be synergistic.<ref name="freeman"/>
 +
* Lithium’s pharmacokinetics are not changed by valproate.<ref name="freeman"/>
 +
* There may be additive adverse reactions due to this combination, such as weight gain, sedation, gastrointestinal complaints, and tremor.<ref name="freeman"/>
 +
 
 
| start =  
 
| start =  
 
* Start lithium acid according to the general dosing advice.
 
* Start lithium acid according to the general dosing advice.
 
| cave =  
 
| cave =  
 
}}
 
}}

Latest revision as of 08:38, 23 April 2010

Valproic acid
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AG01
PubChem 3121
PubMed acid%22 Valproic acid
Drugs.com valproic-acid
Kompas (Dutch) Valproic acid
Wikipedia Valproic acid
Lithium
Type moodstabilizer
Group other
links
ATC-code N05AN01
Medscape Lithium
PubChem 11125
PubMed Lithium
Drugs.com lithium
Kompas (Dutch) Lithium
Wikipedia Lithium

Adding lithium to valproic acid.

Infobord.png General information
  • Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
  • Lithium is eliminated by the kidney for about 95%. Changes in the rate of excretion can cause unwanted effects.
  • Lithium and valproic acid are the most commonly used mood-stabilizing agents.[4]
  • The combination of lithium and valproate appears to be well tolerated and effective in treating bipolar illness.[4]
  • Addition of lithium to valproic acid is the treatment of choice for acute mania with partial but inadequate response to valproate.[4]
  • This combination may be synergistic.[4]
  • Lithium’s pharmacokinetics are not changed by valproate.[4]
  • There may be additive adverse reactions due to this combination, such as weight gain, sedation, gastrointestinal complaints, and tremor.[4]
Eenrichtingbord.png Start lithium
  • Start lithium acid according to the general dosing advice.



  1. Farmacotherapeutisch Kompas; Toxicologie (dutch)
  2. 2.0 2.1 Farmacotherapeutisch Kompas - valproinezuur (dutch) Cite error: Invalid <ref> tag; name "ftk" defined multiple times with different content
  3. KNMP; Informatorium Medicamentorum 2023; Monografie "valproaat" (Dutch)
  4. 4.0 4.1 4.2 4.3 4.4 4.5 Freeman et al. Mood stabilizer Combinations: A Review of Safety and Efficacy. Am J Psychiatry 1998;155:12-21
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.